Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | CDK8 | P49336 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18037976 | 0.93 | MAPT (0.55) | KMT2AMAPTMEN1NPC1LMNA | |
| SCHEMBL18017326 | 0.88 | MAPT (0.43) | KMT2AMAPTMEN1NPC1LMNA | |
| SCHEMBL25858253 | 0.88 | BLM (0.50) | KMT2AMAPTMEN1NPC1LMNA | |
| SCHEMBL17985623 | 0.81 | MAPT (0.50) | KMT2AMAPTMEN1NPC1LMNA | |
| SCHEMBL18037977 | 0.81 | LMNA (0.56) | KMT2AMAPTMEN1NPC1LMNA | |
| SCHEMBL18017330 | 0.76 | LMNA (0.43) | MAPTNPC1LMNAHTTBLM | |
| SCHEMBL25858259 | 0.73 | BLM (0.52) | KMT2AMAPTMEN1NPC1LMNA | |
| SCHEMBL24009862 | 0.73 | KMT2A (0.58) | KMT2AMAPTMEN1NPC1LMNA | |
| SCHEMBL25858218 | 0.72 | SLC2A1 (0.60) | KMT2AMAPTNPC1TP53BLM | |
| SCHEMBL17985546 | 0.72 | GRM5 (0.39) | KMT2AMAPTLMNAHTTGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271926-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. | 2023-08-31 | — | — | US | disclosed |
| US-11691951-B2 | Inhibition of Olig2 activity | Curtana Pharmaceuticals, Inc. (US) | 2023-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691951-B2 | Inhibition of Olig2 activity | GLI2, ING2, GMFG | KMT2A 501/4885MAPT 1722/4885MEN1 2974/4885 |
| US-20230271926-A1 | INHIBITION OF OLIG2 ACTIVITY | GLI2, ING2, GMFG | KMT2A 501/4885MAPT 1722/4885MEN1 2974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.